|
[1]
|
Phase IV Metabolism
Gastroenterology Clinics of North America,
2025
DOI:10.1016/j.gtc.2024.11.004
|
|
|
|
|
[2]
|
One‐carbon metabolism and microbial pathogenicity
Molecular Oral Microbiology,
2024
DOI:10.1111/omi.12417
|
|
|
|
|
[3]
|
Kinetic Properties of Glutamate Carboxypeptidase II Partially Purified from Leukodystrophy Patient’s Serum
ACS Chemical Neuroscience,
2024
DOI:10.1021/acschemneuro.4c00366
|
|
|
|
|
[4]
|
SIMMER employs similarity algorithms to accurately identify human gut microbiome species and enzymes capable of known chemical transformations
eLife,
2023
DOI:10.7554/eLife.82401
|
|
|
|
|
[5]
|
Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
Microbiome Research Reports,
2023
DOI:10.20517/mrr.2023.41
|
|
|
|
|
[6]
|
Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease
Frontiers in Microbiology,
2023
DOI:10.3389/fmicb.2023.1107976
|
|
|
|
|
[7]
|
Understanding the mechanisms of halotolerance in members of Pontixanthobacter and Allopontixanthobacter by comparative genome analysis
Frontiers in Microbiology,
2023
DOI:10.3389/fmicb.2023.1111472
|
|
|
|
|
[8]
|
Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response
Frontiers in Immunology,
2021
DOI:10.3389/fimmu.2021.789334
|
|
|
|
|
[9]
|
A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague–Dawley Rats
Journal of Proteome Research,
2020
DOI:10.1021/acs.jproteome.0c00230
|
|
|
|
|
[10]
|
A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague–Dawley Rats
Journal of Proteome Research,
2020
DOI:10.1021/acs.jproteome.0c00230
|
|
|
|
|
[11]
|
Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis
AIMS Microbiology,
2018
DOI:10.3934/microbiol.2018.4.642
|
|
|
|